Navigation Links
5 more pharmaceutical companies join NIH initiative to speed therapeutic discovery
Date:6/12/2012

Five additional pharmaceutical companies have joined a National Institutes of Health-led effort to help scientists research promising new treatments for patients. Funding and molecular compound information is available now for the initial phase of the recently unveiled Discovering New Therapeutic Uses for Existing Molecules program. This NIH-industry collaboration will match researchers with 58 compounds to test ideas for new therapeutic uses. Since the launch of the program last month, the total number of compounds the companies are making available has more than doubled.

Abbott, Bristol-Myers Squibb Company, GlaxoSmithKline, Janssen Pharmaceutical Research & Development, L.L.C., and Sanofi have joined Pfizer, AstraZeneca, and Eli Lilly and Company in this innovative approach to research.

The NIH's new National Center for Advancing Translational Sciences (NCATS) created the Therapeutics Discovery program to help re-engineer the research pipeline. By crowdsourcing compounds that already have cleared several key steps in the development process, including safety testing in humans, scientists nationwide have the opportunity to contribute their expertise to advancing these resources for new disease therapies.

The eight participating companies will provide their compounds and related data, which were determined by the NIH to meet specific eligibility criteria. For example, each compound must have advanced to clinical studies but been unsuccessful in its original therapeutic indication or not pursued for business reasons. Preliminary information about the compounds, including mechanism of action, route of administration, and any limitations in use based on safety and tolerability, are available at http://ncats.nih.gov/therapeutics-directory.html.

"Each company participating in this innovative collaboration has made substantial research and development investments to advance these compounds to the point where they can be used in clinical studies," said Kathy L. Hudson, Ph.D., NCATS acting deputy director. "If researchers funded through this effort can demonstrate new uses for the compounds, they could significantly reduce the amount of time it takes to get a treatment to patients in need."

For the pilot phase of the program, in fiscal year 2013, NCATS will provide up to $20 million to fund two- to three-year staged, cooperative agreement research grants. If specific milestones are met, funded researchers will conduct pre-clinical validation and clinical feasibility studies in the first stage, and proof-of-concept clinical trials in the second stage, to test whether one of the compounds may be effective against a previously unexplored disease target. The pilot phase also is intended to test the utility of the newly created template agreements by reducing the negotiation time that otherwise could delay the research.


'/>"/>

Contact: Bobbi Gardner
gardnerbw@mail.nih.gov
301-443-9919
NIH/National Center for Research Resources
Source:Eurekalert

Related medicine news :

1. Nobel laureate to keynote international pharmaceutical conference at URI
2. MSU invention could help pharmaceutical industry save money
3. Global, common approach to pharmaceutical supply chain integrity the focus of workshop
4. Georgia Tech launches HomeLab to help companies evaluate home health technologies
5. Kudos for 3 NJIT Enterprise Development Center high-tech companies
6. New initiative aims to increase mobility for disabled children worldwide
7. National initiative launched to change the way biology departments approach undergraduate education
8. Researchers creating designer lymph nodes based on Moffitts Total Cancer Care initiative
9. U.S. Spends Too Little on Public Health Initiatives: Report
10. Program to coordinate regional systems to speed heart attack care
11. Advanced genetic screening method may speed vaccine development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... 2016 , ... More than half of American teens report losing their virginity ... with their child about sex related topics, less than 60 percent spoke about deeper ... announce the launch of its second edition of the “Sexual Wellness” campaign, aiming to ...
(Date:12/2/2016)... ... December 02, 2016 , ... Universal Medical ... systems and the first company to offer robotic imaging to veterinary medicine is ... booth # 941 for the American Association of Equine Practitioners 62nd Annual Convention ...
(Date:12/2/2016)... ... ... "Pro3rd Accents Volume 2 is a set of 30 accented lower third ... a few clicks of the mouse," said Christina Austin - CEO of Pixel Film ... various styles with accented animations, rigid boxes, simplistic lines, and more. In Addition, users ...
(Date:12/2/2016)... ... December 02, 2016 , ... Date aired: November 28, ... 2 Diabetes: The Owner’s Manual, http://realtimepressrelease.com/press-releases-tagged-with/daryl-wein , Sharon Kleyne, America’s ... Global Climate Change and Your Health radio program syndicated on Voice of America, ...
(Date:11/30/2016)... ... November 30, 2016 , ... "I hate when the mixture of saliva and ... said an inventor from Bridgewater, N.J. "I thought that there had to be a ... He developed the patent-pending DEFLECTOR to prevent saliva and toothpaste from running down the ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... NEW YORK , December 2, 2016 ... at 5,251.11, down 1.36%; the Dow Jones Industrial Average edged ... closed at 2,191.08, down 0.35%. Losses were broad based as ... Today, Stock-Callers.com has initiated research reports on the following Services ... N.V. (NASDAQ: QGEN ), INC Research Holdings Inc. ...
(Date:12/2/2016)... -- UCB is pleased to announce that 12 scientific abstracts have ... American Epilepsy Society (AES) Annual Meeting, which takes place ... USA. 1-12 Data being presented include ... ® (lacosamide) CV and BRIVIACT ® (brivaracetam) CV. ... state of the union of epilepsy care and antiepileptic drugs ...
(Date:11/30/2016)... 30, 2016 Research and Markets ... for Neuromodulation, Neurovascular, Neurosurgical and Monitoring Devices 2017 - MedView" ... ... The full report suite on the U.S. market for ... systems, intracranial pressure monitoring devices, detachable coils, liquid embolics, catheters, ...
Breaking Medicine Technology: